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Background and purpose: The availability and promise of effective treatments for neurodegenerative disorders are 
increasing the importance of early diagnosis. Having molecular and biochemical markers of Alzheimer’s disease (AD) 
would complement clinical approaches, and further the goals of early and accurate diagnosis. Combining multiple 
biomarkers in evaluations significantly increases the sensitivity and specificity of the biochemical tests.
Methods: In this study, we used color-coded bead-based Luminex technology to test the potential of using 
chemokines and cytokines as biochemical markers of AD. We measured the levels of 22 chemokines and cytokines 
in the serum and cerebrospinal fluid (CSF) of 32 de novo patients (13 controls, 11 AD, and 8 Parkinson’s disease 
[PD]).
Results: MCP-1 was the only cytokine detectable in CSF, and its levels did not differ between control and disease 
groups. However, the serum concentration of eotaxin was significantly higher in AD patients than in the control 
group.
Conclusions: The analysis of multiple inflammatory mediators revealed marginal differences in their CSF and serum 
concentrations for the differential diagnosis of AD and PD. These results provide evidence that immunological 
responses are not major contributors to the pathogenesis of AD and PD.
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INTRODUCTION
The promising developments in effective treatments 
for neurodegenerative disorders are increasing the 
demand and urgency for the early and accurate diag-
nosis of dementia.
1 Alzheimer’s disease (AD) is the 
most common form of dementia, for which the sensiti-
vity of clinical diagnosis is relatively high; however, 
the specificity was lower than 60% in a multicenter 
clinical-autopsy study.
2 Even though the predictability 
of a clinical diagnosis of AD becomes as high as 
90% in specialized institutions, very early diagnosis 
of AD remains a challenge in many clinical settings.Choi CL, et al. Multiplex Analysisof Cytokines in the Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease by Color-Coded Bead Technology
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At present, diagnosing AD and distinguishing it 
from other dementias depend primarily on clinical 
evaluation, and ultimately on clinical judgment. Know-
ledge of molecular and biochemical markers of AD 
would complement clinical approaches, and further 
the goals of early and accurate diagnosis. The proposed 
criteria for an ideal biomarker of AD includes a 
sensitivity >80% for detecting AD and a specificity 
of >80% for distinguishing it from other dementias.
3 
Combined evaluations with multiple biomarkers signi-
ficantly increase the sensitivity and specificity of the 
biochemical tests,
4 which has prompted several research 
groups to develop innovative methods for simultaneously 
quantifying multiple biomarkers in the serum and cere-
brospinal fluid (CSF) using solution-based protein chip 
analysis.
5,6
MATERIALS AND METHODS
1. Patients
This study was approved by the ethics committees 
of Ewha University, and all patients and/or their 
caregivers gave their informed consent. AD and 
Parkinson’s disease (PD) patients were diagnosed 
according to the criteria of the National Institute of 
Neurological and Communicative Disorders and the 
Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA), and the UK Parkinson’s 
Disease Society Brain Bank.
7-9 Normal healthy controls 
without neurological involvement were included for 
comparison. All patients underwent a standard battery 
of medical and neuropsychological tests, brain magnetic 
resonance imaging or computed tomography and, if 
indicated, positron-emission computed tomography. 
Patients with recent infections (occurring less than 2 
months previously), signs of chronic inflammation, and 
using any medications related to neurologic symptoms 
and nonsteroidal anti-inflammatory drugs were excluded.
2. Multiplex analysis of cytokines
In this study, we used Luminex xMAP technology 
for multiplexed quantification of 22 cytokines in the 
serum and CSF.
6 Lumbar punctures were performed 
with the patient in the recumbent position according 
to a standard procedure. The multiplexing analysis 
was performed using the Luminex
TM 100 system 
(Luminex, Austin, TX, USA) by the diagnostic kit 
development team of Ab Frontier (Suwon, Korea). 
Twenty-two cytokines (IL-1α, IL-1β, IL-2, IL-3, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL- 
12p70, IL-13, IL-15, TNF-α, interferon-γ, GM-CSF, 
eotaxin, IP-10, MIP-1α, MCP-1, and RANTES) were 
simultaneously measured in the serum and CSF using 
a Beadlyte Human Multicytokine Beadmaster kit (Up-
state, Lake Placid, NY, USA) according to the manu-
facturer’s protocol. The sensitivity of these bead sets 
was 0.1-10 pg/mL. Total tau and Aβ42 in serum and 
CSF were simultaneously analyzed using human total 
tau and Aβ42 antibody bead kits (Biosource, Camarillo, 
CA, USA) according to the manufacturer’s protocol.
3. Statistical analysis
Biomarkers in the patient groups were analyzed 
statistically using ANOVA with Tukey’s honest signi-
ficant-difference post-hoc test applied to significant 
main effects (SPSS version 12.0K for Windows, SPSS, 
Chicago, IL, USA).
RESULTS
A total of 32 patients were enrolled, comprising 13 
controls, 11 AD, and 8 PD patients (Table). Before 
analyzing multiple cytokines, we first examined the 
levels of total tau and Aβ42 in the CSF samples to 
confirm whether our study protocol could reproduce 
the same results for the levels of tau and Aβ42 in 
AD and PD. It has been well documented that the 
CSF levels of Aβ decline while those of total tau 
increase in AD patients.
4,10,11 Consistent with previous 
reports, we also observed a significant decrease in A
β42 but no significant increase in total tau (data not 
shown). 
Since the Aβ42 and tau profiles were compatible Journal of Clinical Neurology: Vol. 4, No. 2, 2008
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Table. Demographic data and analysis of serum and CSF levels of biomarkers
Control AD PD F2,31, P*
Number (M/F) 13 (5/8) 11 (2/9) 8 (0/8) 1.94, 0.16
Age (years) 68.5±7.2 73.5±4.0 73.0±8.6 1.42, 0.26
Serum levels of cytokines (ng/mL)
IL-1α   6.1±21.6 n.d.
†  1.8±5.0 0.60, 0.56
IL-4 14.4±2.8 13.8±0.6 13.6±0.3 0.66, 0.53
IL-5  9.4±0.8  9.1±0.3  9.1±0.2 0.65, 0.53
IL-7  40.7±11.1 37.2±3.1 37.0±1.0 0.91, 0.41
IL-8 11.8±5.2 11.0±1.3 10.6±0.3 0.38, 0.69
IL-12p40  39.3±19.3  60.8±22.6  60.4±32.7 2.98, 0.07
IL-12p70 22.7±9.8 21.8±6.7  23.1±12.8 0.05, 0.96
IL-13  19.6±11.0  32.1±21.5 23.6±8.2 2.09, 0.14
Interferon-γ  22.2±13.7  34.0±28.4  31.3±10.4 1.19, 0.32
GM-CSF  24.1±13.9 25.5±9.8  24.5±12.5 0.04, 0.96
Eotaxin    6.9±10.0
c‡   23.0±24.8
‡  21.9±19.3 3.42, 0.047
IP-10  2.2±0.2  4.3±0.4  3.7±0.4 2.40, 0.11
MCP-1 11.4±7.7  22.3±31.9  15.9±10.5 0.87, 0.43
MIP-1α  5.1±3.1  14.2±17.6  13.3±21.0 1.37, 0.27
RANTES  9.9±0.2  1.1±0.9  1.1±0.2 1.90, 0.17
TNF-α  26.8±18.7  34.7±22.8  30.6±22.2 0.43, 0.66
CSF concentrations of cytokines (ng/mL)
MCP-1 1.8±0.6  2.0±1.1  3.4±4.3 1.63, 0.22
Aβ42 0.4±0.2  0.3±0.1
‡  0.6±0.4
‡ 3.27, 0.04
tau 0.9±0.5 1.2±0.9 0.4±0.2 1.71, 0.19
F, females; M, males.
*ANOVA (between groups) 
†n.d., not detected 
‡Tukey’s post-hoc test applied to significant effect of group ANOVA, p < 0.05. 
Data are mean±SD values.
with previous reports, we next applied the multiplexed 
analysis of 22 cytokines and chemokines to the samples. 
In the CSF, only MCP-1 was detectable, with the 
levels not differing significantly between the control 
and disease groups. Fifteen of the 22 analyzed cytokines 
were detectable in the serum samples. Interestingly, 
the serum concentration of eotaxin (which is a chemo-
tactic factor for eosinophil) was significantly higher 
in AD patients than in controls. IL-12p40 was also 
elevated in both AD and PD, while IL-12p70 did not 
differ significantly between the disease groups. Inter-
feron-γ, MIP-1α, and IP-10 were elevated in both 
AD and PD patients, but the differences from controls 
were not statistically significant.
DISCUSSION
Among 22 cytokines and chemokines, only eotaxin 
was significantly elevated in the serum of AD patients 
compared to the controls. This is not consistent with 
a previous report that the CSF levels of IL-8, IP-10, 
and MCP-1 were increased in AD patients.
12 This 
discrepancy might be partly due to differences in the 
sensitivities of the different assays used and in patient 
characteristics. Since we enrolled de novo patients 
who had no history of medication related to neurologic 
symptoms, our cohort might have comprised patients 
with relatively mild conditions and in the early stage 
compared to previous studies. To our knowledge, in-
creased levels of eotaxin have not been related to any 
neurologic disorders without autoimmune components. 
Increased levels of eotaxin have been reported in 
ischemic coronary diseases, obesity, and allergic dis-
orders such as asthma, parasitic infections, and allergic 
respiratory diseases.
13,14 The significance of increased 
eotaxin in AD is currently unclear. IL-12p40 was 
also elevated in both AD and PD, while IL-12p70 Choi CL, et al. Multiplex Analysisof Cytokines in the Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease by Color-Coded Bead Technology
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did not differ significantly between the disease groups. 
IL-12 has been implicated in proinflammatory responses 
to bacterial infection and in recovery after interferon 
treatment.
15,16  However, confirming these preliminary 
results requires longitudinal analysis of a larger group 
of patients.
Interestingly, the levels of Aβ42 and tau differed 
between the PD group and the control and AD groups, 
with a decrease in CSF tau and increase in Aβ42 in 
PD. This finding is opposite those of previous studies 
showing that tau protein levels were significantly 
higher and Aβ42 lower in PD patients than in AD 
patients and controls.
17,18 This discrepancy might be due 
to the small numbers of patients and the selection of 
nondemented patients in our study. The combined 
analysis of total tau and Aβ42 not only facilitated 
the clear distinction between AD and controls but 
also better differentiation between AD and PD.
Since CSF is directly contiguous with the central 
nervous system, we initially expected that any changes 
in immunological responses related to neurodegeneration 
would be predominantly reflected in the CSF. However, 
we instead observed significant differences in the pattern 
of a proinflammatory biomarker in the serum (and 
not in the CSF) between control and AD patients. 
Even though the lumbar puncture is a relatively easy 
procedure with a low incidence of complications, it is 
highly preferable to use blood samples for biochemical 
analysis, especially for screening purposes.
1
Since the present study demonstrated differences 
in a proinflammatory mediator in AD and PD patients, 
the further exploration and development of surrogate 
biomarkers for neurodegenerative disorders might yield 
useful tools for the differential diagnosis of dementia, 
for monitoring disease progression and the therapeutic 
efficacy of potential treatments, and also for improving 
the understanding of the underlying pathological me-
chanisms.
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